More ASCO – anti-LAG-3 plus anti-PD-1 and new drug added to the ipi/nivo combo

If I might add to the ipi+nivo + Tocilizumab (IL-6) drug information, which looks very interesting, one video from 2019. Dr. Weber in a 4 min video explains the thinking behind the trial and why they are going down this pathway and explains where the data came from and what their hope is in the trial. Also one little addition to your blog, the clinical trial needs another “9” at the end of the trial #, so it should read NCT03999749. Here is Weber from 2019 on adding Tocilizumab. https://www.cancertherapyadvisor.com/home/news/conference-coverage/american-society-of-clinical-oncology-asco/asco-2019/melanoma-inhibitors-elevated-levels-of-serum-crp-il6-biomarkers-poor-prognosis/

I was one of the rats in this case, received Nivo+Ipi+Toci last year, but not as a trial.  I had received the toci to manage the effects of another trial, but continued it into nivo+ipi coming off of that.  I think my doctor might have made a unique maneuver with the insurance for them to approve it, because they refused to continue after the first or second dose lol.  I have some residual brain fog from that trial so pardon me if the timeline is off, but the trio worked very well for me.  I didn’t develop colitis except maybe a little towards the end, where when I was on ipi+nivo previously I had to be hospitalized for severe duodenitis.